Home
October 2009 November 2009 December 2009
Su Mo Tu We Th Fr Sa
Week 45 1 2 3 4 5 6 7
Week 46 8 9 10 11 12 13 14
Week 47 15 16 17 18 19 20 21
Week 48 22 23 24 25 26 27 28
Week 49 29 30
Reach urologists

The Current Role of Telomerase in the Diagnosis of Bladder Cancer - Abstract Show Comments PDF Print E-mail
  
Tuesday, 23 June 2009

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Via Piero Maroncelli 40, 47014 Meldola (FC), Italy.

Bladder cancer has an incidence of 15 cases per 100,000 persons in the global population and is the most common tumor of the urinary tract. Imaging techniques, cytoscopy, and cytology are either invasive or not sufficiently accurate to detect early stage tumors, and the need for new diagnostic markers still remains. Among the markers most recently proposed to improve diagnostic accuracy and especially sensitivity, increasing attention has been focused on the role of the ribonucleoprotein, telomerase. Relevant papers on the etiology, diagnosis, and evaluation of bladder cancer using telomerase in urine were searched for and considered. The PubMed search was performed using the text terms "bladder cancer", "diagnosis", and "telomerase". Previous studies have shown that the quantitative Telomerase Repeat Amplification Protocol (TRAP) assay performed in voided urine is an important non-invasive tool for the diagnosis of bladder tumors since it has very high sensitivity and specificity, even for early stage and low grade tumors. The main limitation of this test is the rate of false positive results due to the presence of inflammatory or non-tumor cells (i.e., epithelial cells from the lower genital tract), which express telomerase activity (TA). Consequently, an in situ analysis would seem to be important to identify the nature of telomerase-positive cells. Immunocytochemical detection of the hTERT subunit by a specific antibody seemed to open up the possibility to identify different cellular components of urine. However, the lack of a strict relationship between hTERT protein expression and telomerase activity has, to a certain extent, made this approach less relevant. In conclusion, telomerase activity in urine determined by TRAP seems to be marker of great potential, even more advantageous in cost/benefit terms when used in selected symptomatic patients or professionally high-risk subgroups.

Written by:
Bravaccini S, Casadio V, Amadori D, Calistri D, Silvestrini R. Are you the author?

Reference:
Indian J Urol. 2009 Jan;25(1):40-6.
doi:10.4103/0970-1591.45535

PubMed Abstract
PMID:19468427

UroToday.com Bladder Cancer Section

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 2
PoorBest


 
Visitor Ratings:
No Affiliation:
5 (6 votes)


Bookmark and Share

Member's Section

Login

Sign Up

Quick Search

Meet the Expert


All Experts


Featured Conference

Media and Publisher

Advertising Rates
Reprints

Working with Industry

Case Studies
Sponsorship Opportunities

Bladder Cancer
Sponsored By